Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F16%3A00065878" target="_blank" >RIV/00159816:_____/16:00065878 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00092187

Výsledek na webu

<a href="http://dx.doi.org/10.2217/cer-2016-0020" target="_blank" >http://dx.doi.org/10.2217/cer-2016-0020</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2217/cer-2016-0020" target="_blank" >10.2217/cer-2016-0020</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe

Popis výsledku v původním jazyce

Aim: Adalimumab effectiveness on clinical, functional and work-related outcomes was evaluated in patients with active ankylosing spondylitis or psoriatic arthritis treated in routine clinical practice in central-eastern Europe. Methods: Patients (n = 555) were followed for 12 months. Primary end point was percentage of patients with a treatment response (}= 50% decrease from baseline in Bath Ankylosing Spondylitis Disease Activity Index or }= 1.2 point decrease from baseline in Disease Activity Index-28 joint for axial or peripheral symptoms, respectively). Functional status was evaluated by the Bath Ankylosing Spondylitis Functional Index and Health Assessment Questionnaire Disability Index. Working ability was evaluated by the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem. Results: 76.1% of patients with axial symptoms and 83.5% with peripheral symptoms achieved a treatment response. Frequency of extra-articular manifestations decreased. Improvements were observed in functional status and workability. No new safety signals were observed. Conclusion: Adalimumab was effective and well tolerated during real-world use in central-eastern Europe.

Název v anglickém jazyce

Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe

Popis výsledku anglicky

Aim: Adalimumab effectiveness on clinical, functional and work-related outcomes was evaluated in patients with active ankylosing spondylitis or psoriatic arthritis treated in routine clinical practice in central-eastern Europe. Methods: Patients (n = 555) were followed for 12 months. Primary end point was percentage of patients with a treatment response (}= 50% decrease from baseline in Bath Ankylosing Spondylitis Disease Activity Index or }= 1.2 point decrease from baseline in Disease Activity Index-28 joint for axial or peripheral symptoms, respectively). Functional status was evaluated by the Bath Ankylosing Spondylitis Functional Index and Health Assessment Questionnaire Disability Index. Working ability was evaluated by the Work Productivity and Activity Impairment Questionnaire - Specific Health Problem. Results: 76.1% of patients with axial symptoms and 83.5% with peripheral symptoms achieved a treatment response. Frequency of extra-articular manifestations decreased. Improvements were observed in functional status and workability. No new safety signals were observed. Conclusion: Adalimumab was effective and well tolerated during real-world use in central-eastern Europe.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Comparative Effectiveness Research

ISSN

2042-6305

e-ISSN

—

Svazek periodika

5

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

475-485

Kód UT WoS článku

000380807700006

EID výsledku v databázi Scopus

—